Lucence Diagnostics, A*STAR’s DxD Hub and the National Cancer Centre Singapore launched UNITED 2.0, a S$6 million collaboration to develop a clinical, AI‑augmented whole‑genome and whole‑transcriptome tumor profiling assay. The project targets actionable mutation and fusion detection across multiple cancer types and plans a minimal residual disease tool for post‑treatment surveillance. The partners said UNITED 2.0 builds on an existing tissue test and will integrate AI analytics and patient‑centered design through a formal framework with patient groups. The initiative underlines regional investments in high‑definition precision oncology infrastructure. Source: joint press release and CEO statements.